NASDAQ:XERS
Xeris Pharmaceuticals Inc Stock News
$1.98
-0.0400 (-1.98%)
At Close: May 17, 2024
Xeris Pharmaceuticals (XERS) Reports Q4 Loss, Misses Revenue Estimates
09:06am, Tuesday, 09'th Mar 2021
Xeris Pharmaceuticals (XERS) delivered earnings and revenue surprises of -5.13% and -22.83%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the sto
Xeris Pharmaceuticals Reports Fourth Quarter and Full-year 2020 Financial Results and Recent Highlights
07:00am, Tuesday, 09'th Mar 2021
CHICAGO--(BUSINESS WIRE)-- #T1D--Xeris Pharmaceuticals, Inc. (Nasdaq: XERS), a specialty pharmaceutical company leveraging its novel formulation technology platforms to develop and commercialize ready
Earnings Outlook for Xeris Pharmaceuticals
10:14am, Monday, 08'th Mar 2021
Xeris Pharmaceuticals (NASDAQ:XERS) unveils its next round of earnings this Tuesday, March 09. Get prepared with Benzinga's ultimate preview for Xeris Pharmaceuticals's Q4 earnings.
CHICAGO--(BUSINESS WIRE)--Xeris Pharmaceuticals, Inc. (Nasdaq: XERS), a specialty pharmaceutical company leveraging its novel formulation technology platforms to develop and commercialize ready-to-use
Xeris Pharmaceuticals Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
04:05pm, Friday, 26'th Feb 2021
CHICAGO--(BUSINESS WIRE)--Xeris Pharmaceuticals, Inc. (Nasdaq: XERS), a specialty pharmaceutical company leveraging its novel technology platforms to develop and commercialize ready-to-use injectable
Xeris Pharmaceuticals to Webcast Upcoming Investor Conference Presentations
08:00am, Thursday, 18'th Feb 2021
CHICAGO--(BUSINESS WIRE)--Xeris Pharmaceuticals, Inc. (Nasdaq: XERS), a specialty pharmaceutical company leveraging its novel technology platforms to develop and commercialize ready-to-use injectable
Xeris: Recent Success Warrants A Closer Look
10:22am, Wednesday, 17'th Feb 2021
Xeris Pharmaceuticals continues to pop up on my newsfeed and momentum scanners. Unfortunately, I threw XERS in my speculative portfolio's closet and haven't paid attention despite it hitting new 52-we
XERS Stock Price Increases Over 20% Pre-Market: Why It Happened
06:49am, Friday, 12'th Feb 2021
The stock price of Xeris Pharmaceuticals Inc (NASDAQ: XERS) is trading at over 20% pre-market. This is why it happened.
Xeris Pharma's Hypoglycemia Med Receives European Nod, Shares Spike
06:06am, Friday, 12'th Feb 2021
The European Commission has approved Xeris Pharmaceuticals Inc's (NASDAQ: XERS) Ogluo (glucagon) injection to treat severe hypoglycemia in adults, adolescents, and children aged two years and over
CHICAGO & DUBLIN--(BUSINESS WIRE)-- #GvokeHypoPen--Xeris Pharmaceuticals, Inc. (Nasdaq: XERS), a specialty pharmaceutical company leveraging its novel formulation technology platforms to develop and c
Xeris Pharmaceuticals Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
04:05pm, Friday, 29'th Jan 2021
CHICAGO--(BUSINESS WIRE)--Xeris Pharmaceuticals, Inc. (Nasdaq: XERS), a specialty pharmaceutical company leveraging its novel technology platforms to develop and commercialize ready-to-use injectable
Xeris Pharmaceuticals to Participate in H.C. Wainwright BioConnect 2021 Virtual Conference
04:05pm, Tuesday, 05'th Jan 2021
CHICAGO--(BUSINESS WIRE)-- #GvokeHypoPen--Xeris Pharmaceuticals, Inc. (Nasdaq: XERS), a specialty pharmaceutical company leveraging its novel technology platforms to develop and commercialize ready-to
Xeris Pharmaceuticals Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
04:05pm, Thursday, 31'st Dec 2020
CHICAGO--(BUSINESS WIRE)--Xeris Pharmaceuticals, Inc. (NASDAQ: XERS), a specialty pharmaceutical company leveraging its novel technology platforms to develop and commercialize ready-to-use injectable
CHICAGO--(BUSINESS WIRE)-- #GvokeHypoPen--Xeris Pharmaceuticals, Inc. (Nasdaq: XERS), a specialty pharmaceutical company leveraging its novel formulation technology platforms to develop and commercial
Do Options Traders Know Something About Xeris Pharmaceuticals (XERS) Stock We Don't?
10:32am, Wednesday, 16'th Dec 2020
Investors need to pay close attention to Xeris Pharmaceuticals (XERS) stock based on the movements in the options market lately.
